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New Perspectives into the Review
Molecular Pathogenesis and
Treatment of Type 2 Diabetes
disposal occurs in skeletal muscle, whereas fasting
plasma glucose levels are determined primarily by glu-
cose output from the liver.
The balance between the utilization and production
of glucose is maintained at equilibrium by two opposing
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hormones, insulin and glucagon. In response to an ele-
vation in plasma glucose and amino acids (after con-
sumption of a meal), insulin is released from the b cells
There is little doubt that we are in the midst of a world- of the islets of Langerhans in the pancreas. The glucose
wide epidemic of diabetes. There are an estimated 143 is transported into b cells via the Glut2 transporter,
million people worldwide with the disease, almost five which has a relatively low affinity for glucose, such that
times more than estimates of ten years ago. This number the rate of glucose transport changes with fluctuations
will probably double by 2030 (Harris et al., 1998). Al- in blood glucose concentration. The b cells contain a
though diabetes is more prevalent in developed coun- specific glucokinase that exhibits a low affinity for glu-
tries, it is likely that the developing world will bear the cose, and is not inhibited by product formation, thus
brunt of the epidemic in the future. In the U.S., almost enabling the enzyme to adjust its activity in response
16 million people are thought to be afflicted, a third of to a wide range of glucose concentrations. After phos-
whom are undiagnosed. The disease is considerably phorylation, glucose is oxidized and ATP is generated.
more common among the elderly and strikes African-, The increased ATP/ADP ratio closes potassium chan-
Mexican- and Native Americans at 1.7–3 times the rate nels, and the cell becomes depolarized. This results
for that of non-Hispanic whites. In patients with diabe- in the opening of voltage-sensitive calcium channels,
tes, the risk of heart disease and stroke are elevated which increases intracellular calcium and thus stimu-
2–4 times. Moreover, diabetes is the leading cause of lates the fusion of the insulin-containing secretory vesi-
end stage renal disease, blindness, and nontraumatic cles with the plasma membrane, resulting in the pulsatile
limb amputation. While the human and economic costs release of insulin. When plasma glucose falls (during
of diabetes are difficult to calculate, the total medical fasting or exercise), glucagon is secreted by a cells,
costs incurred annually in the U.S. alone are close to which surround the b cells in the pancreas. Both a and
$100 billion. b cells are extremely sensitive to glucose concentrations
Diabetes is defined as a state in which carbohydrate and can regulate hormone synthesis and release in re-
and lipid metabolism are improperly regulated by insulin. sponse to small changes in plasma glucose levels. Insu-
This results in elevated fasting and postprandial serum lin stimulates glucose uptake, utilization, and storage,
glucose that leads to complications if left untreated. while suppressing hepatic glucose production, thus re-
There are two major categories of the disease, Types ducing plasma glucose levels. Glucagon promotes the
1 and 2. Patients with Type 1 diabetes are absolutely release of stored and newly synthesized glucose into
dependent on exogenous insulin. This form of the dis- the bloodstream. These two hormones act in concert to
ease may account for 5%–10% of all cases and is ensure that glucose homeostasis is maintained through-
thought to result from the autoimmune destruction of out a wide variety of physiological conditions.
the insulin-producing b cells of the islets of Langerhans. The primary targets for insulin are skeletal and cardiac
Type 2 diabetes is far more common and results from muscle, adipose tissue and liver. Glucose uptake is the
a combination of defects in insulin secretion and action. rate-limiting step in glucose utilization and storage. In-
While the complications that arise from these two forms sulin stimulates the transport of glucose into muscle
of the disease are similar, the diseases are completely and fat cells by increasing the concentration of a specific
glucose transporter isoform, Glut4, at the cell surface.different entities in terms of pathophysiology. Because
This action of insulin causes a 10- to 40-fold increaseof these major differences, I will restrict the scope of this
in cellular glucose uptake. Upon entering the musclereview to the exciting new insights into the underlying
cell, glucose is rapidly phosphorylated by hexokinasepathophysiology and genetics of Type 2 diabetes, as
and either subsequently stored as glycogen due to thewell as new prospects for therapeutic intervention.
activation of glycogen synthase, or oxidized to generate
ATP synthesis, via activation of enzymes such as pyru-
Hormonal Regulation of Glucose Metabolism
vate kinase. In adipocytes, glucose is stored primarily
A continuous supply of glucose is necessary to ensure as lipid, due to increased uptake of glucose and activa-
proper function and survival of all organs. While hypogly- tion of lipid synthetic enzymes. Insulin also profoundly
cemia produces cellular death, chronic hyperglycemia inhibits lipolysis in adipocytes, primarily through inhibi-
also can result in organ damage. Therefore, the plasma tion of the enzyme hormone sensitive lipase. Most if
glucose level is maintained in a narrow range around 5 not all of these insulin-dependent changes in enzyme
mM, which is considered the physiological set point. activities are mediated by attenuation of their phosphor-
Glucose homeostasis is regulated primarily by the liver ylation state, due to a combination of protein kinase
and skeletal muscle. Following a meal, most glucose inhibition and phophatase activation.
Insulin inhibits the production and release of glucose
by the liver, due to the blockade of gluconeogenesis and* Email: saltiel@umich.edu
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Figure 1. Metabolic Staging of Type 2 Dia-
betes
Type 2 diabetes is characterized by a pro-
gressive decrease in insulin action, followed
by an inability of the b cell to compensate
for insulin resistance. Insulin resistance is the
first lesion, due to interactions among genes,
aging, and metabolic changes produced by
obesity. Insulin resistance in visceral fat leads
to increased fatty acid production, which ex-
acerbates insulin resistance in liver and mus-
cle. The b cell compensates for insulin resis-
tance by secreting more insulin. Ultimately,
the b cell can no longer compensate, leading
to impaired glucose tolerance, and diabetes.
glycogenolysis. In addition to controlling the activities of 5%–10% of glucose-intolerant patients per year pro-
gress to frank diabetes, which continues to worsen asmetabolic enzymes by covalent modification through
phosphorylation or dephosphorylation as stated above, insulin resistance increases. Adipose and liver cells gen-
erate more fatty acids, the liver produces more glucoseinsulin also regulates the expression of a number of
genes encoding hepatic enzymes. For example, the hor- in an unregulated fashion, and the b cells undergo pro-
gressive decompensation, resulting in the late stagesmone dramatically inhibits the transcription of the gene
encoding phosphoenolpyruvate carboxylase (PEPCK), of the disease, where high doses of exogenous insulin
may be required.the rate-limiting step in gluconeogenesis. Just as gluca-
gon reverses many of the covalent modifications of met-
abolic enzymes by insulin, the peptide also exerts op- Signal Transduction Defects in Insulin Action
posing effects on gene transcription. Hepatic cAMP Modifications of the Insulin Receptor
elevation produced by glucagon increases PEPCK gene Insulin resistance results from a combination of genetic
expression during hypoglycemia. Therefore, the activity and environmental factors. It can arise from defects in
of many metabolic enzymes reflects the summation of insulin signal transduction, changes in the expression
signals from both insulin and glucagon receptors, and of proteins or genes that are targets of insulin action,
changes constantly in response to alterations in the cross talk from other hormonal systems, or metabolic
concentration of plasma glucose. abnormalities. One potential site of insulin resistance
may involve the receptor itself. The insulin receptor is
an a2b2 heterotetrameric receptor tyrosine kinase thatMetabolic Staging of Type 2 Diabetes
Insulin resistance, the failure to respond to normal circu- is disulfide-linked. Upon binding insulin, the receptor
undergoes intramolecular transphosphorylation on spe-lating concentrations of insulin, is a common state asso-
ciated with obesity, aging, a sedentary lifestyle, as well cific tyrosine residues, leading to increased kinase
activity toward cellular substrates. Alterations in insulinas a genetic predisposition. The failure of insulin to stim-
ulate glucose uptake in muscle appears to be a primary receptor expression, trafficking, ligand binding, phos-
phorylation, and/or kinase activity have been identifieddefect. Also, in certain fat depots, subsequent resis-
tance to the antilipolytic effects of insulin causes in- in rare cases of severe insulin resistance, such as the
Type A syndrome, leprechaunism, and Rabson-Men-creased lipolysis and fatty acid release. These fatty
acids attenuate the ability of insulin to suppress glucose denhall syndrome (Taylor and Arioglu, 1998). These arise
from point mutations in the receptor, many of whichproduction in the liver, but allow a continual increase in
insulin-stimulated fatty acid synthesis. Thus, this dys- produce a dominant-negative phenotype. In mice, tis-
sue-specific knockout of the insulin receptor in muscleregulation of carbohydrate and lipid metabolism accel-
erates the progression of insulin resistance. b cells of the failed to produce diabetes, instead generating only a
muscle-specific insulin resistance, with little effect onpancreas normally compensate for the insulin resistant
state by increasing basal and postprandial insulin secre- glucose homeostasis (Bruning et al., 1998). In contrast,
disruption of the gene in b cells (Kulkarni et al., 1999)tion, further aggravating insulin resistance. At some
point, the b cells can no longer compensate, failing to or liver (Michael et al., 2000) produced a diabetic pheno-
type. Moreover, elimination of the insulin receptor inrespond appropriately to glucose. This ultimately leads
to the deterioration of glucose homeostasis and the brain produced increased food intake and obesity, and
associated insulin resistance, suggesting a coordinateddevelopment of glucose intolerance, the inability to
properly dispose of glucose (Figure 1). Approximately regulation of brain insulin signaling and energy homeo-
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Figure 2. Tyrosine Kinase Substrates of the
Insulin Receptor
Insulin stimulates the tyrosine kinase activity
of its receptor, leading to the phosphorylation
of a number of cellular substrates, including
Gab1, Shc, IRS 1–4, and Cbl. Upon phosphor-
ylation, each of these proteins can interact
with SH2-containing proteins that direct a
pathway of signal transduction. Gab1 ap-
pears to interact with the SH2 containing
tyrosine phosphatase SHP2, leading to the
activation of the MAP kinase pathway. Phos-
phorylation of Shc produces its binding to the
adaptor protein Grb2, causing activation of
the protooncogene ras, which is also up-
stream of the MAP kinase pathway. The IRS
family of substrates can interact with a num-
ber of SH2 domain proteins. Notable among
these is the regulatory subunit of PI 3-kinase,
which leads to the activation of PIP3-depen-
dent protein kinases such as Akt. This path-
way appears to be required for most of the cellular actions of insulin. The insulin receptor can also phosphorylate Cbl, via its recruitment to
the receptor by the adaptor protein CAP. Upon phosphorylation, Cbl translocates to the lipid raft subdomain of the plasma membrane, where
it interacts with the SH2 domain of the adaptor protein CrkII. This pathway is also necessary for the stimulation of glucose transport by insulin.
IRS, insulin receptor substrate; PI-3K, phosphatidylinositol 3-kinase.
stasis (Bruning et al., 2000). Although care must be taken subunit of phosphatidylinositol (PI) 3-kinase. Activated
PI 3-kinase generates the lipid phosphatidylinositol 3,4,5in interpretation of metabolic studies in rodent models
and their extrapolation to human physiology, these find- trisphosphate (PIP3). Increased PIP3 leads to the activa-
tion of a protein kinase cascade, first stimulating theings challenge the current view of muscle as the primary
site of insulin resistance and suggest an interaction be- protein kinase PDK, which phosphorylates and activates
two classes of serine/threonine kinases, Akt (also knowntween tissues in the regulation of glucose homeostasis
more complex than previously anticipated. Thus, re- as protein kinase B [PKB]), and the atypical protein ki-
nase C isoforms z and l (PKCz/l) (Figure 2). Studiessearch concentrating only on muscle biopsies to mea-
sure the levels or function of genes or proteins involved using pharmacological inhibitors, microinjection of block-
ing antibodies, and expression of dominant-interferingin insulin action may miss critical defects that have indi-
rect effects through other tissues. mutants indicate a necessary role for PI 3-kinase activity
in insulin-stimulated glucose uptake in fat and muscleInsulin Signaling Pathways
Although studies on the genetic forms of extreme insulin cells (Czech and Corvera, 1999). To determine the in
vivo role of PI 3-kinase in glucose homeostasis, miceresistance in humans and in mouse knockouts have
provided a conceptual framework for our understanding were generated with a targeted disruption of the gene
encoding the p85 regulatory subunit of PI 3-kinaseof insulin action, mutations in the insulin receptor are
not common in the general population, suggesting that (Terauchi et al., 1999). Paradoxically, these mice exhibited
increased insulin sensitivity and hypoglycemia due topostreceptor defects represent the primary failures of
insulin action in diabetes. Once activated, the insulin increased glucose transport in skeletal muscle and adi-
pocytes. Although the significance of these findings isreceptor phosphorylates a number of intracellular sub-
strates on tyrosine, including members of the insulin uncertain, it is possible that other isoforms of the regu-
latory protein are increased in compensatory fashion,receptor substrate family (IRS1/2/3/4), the Shc adaptor
protein, Gab-1 and Cbl (Figure 2). Tyrosine phosphoryla- or that p85 exists in excess to the catalytic subunit of
the enzyme, so that a reduction in the expression of thetion of these proteins creates recognition sites for addi-
tional effector molecules containing Src Homology 2 former protein might lead to enhanced activation of the
latter.(SH2) domains. Mice bearing a homozygous disruption
of the IRS1 gene develop a moderate state of insulin There may be a relative decrease in insulin-stimulated
association of IRS proteins with PI 3-kinase and in acti-resistance (Araki et al., 1994; Tamemoto et al., 1994).
These mice do not become diabetic, presumably due vation of Akt in insulin-resistant skeletal muscle (Krook
et al., 1997; Cusi et al., 2000). However, in one study,to b cell compensation. In contrast, homozygous disrup-
tion of the IRS2 gene generates diabetes, due to insu- patients with reduced insulin-stimulated PI 3-kinase
maintained normal activation of Akt, suggesting thatlin resistance coupled with impaired insulin secretion
(Withers et al., 1998). Since skeletal muscle IRS2 does only a relatively small activation of PI 3-kinase is neces-
sary for the full expression of downstream signaling (Kimnot appear to be necessary for insulin- or exercise-stim-
ulated glucose transport, the insulin resistance ob- et al., 1999). These data imply that defects in the path-
way leading from IRS tyrosine phosphorylation to Aktserved in the IRS2 knockout mice might reflect changes
in hepatic insulin action plus alterations in b cell function activation may not be responsible for insulin resistance
in all patients with Type 2 diabetes, although more stud-or survival.
Tyrosine phosphorylation of the IRS proteins induces ies are needed.
Despite the general agreement that PI 3-kinase activ-their binding to the SH2 domains of p85, the regulatory
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ity is necessary for insulin-stimulated glucose uptake, SNARE interactions are essential, neither SNARE pro-
tein appears to be a direct target of insulin action. How-additional signals are required. For example, activation
of PI 3-kinase by PDGF, or interleukin-4, or through ever, the SNARE accessory protein Synip may be in-
volved in the control of Glut4 docking and fusion inengagement of integrin receptors does not stimulate
glucose transport (Pessin and Saltiel, 2000). In addition, an insulin-dependent, PI 3-kinase-independent manner
(Min et al., 1999).two naturally occurring insulin receptor mutations were
fully capable of activating PI 3-kinase, yet were unable Regulation of Glycogen Synthesis Involves
Targeted Signalingto mediate insulin action (Krook et al., 1997). Moreover,
addition of a PIP3 analog had no effect on glucose trans- Studies in cases of early onset insulin resistance (War-
ram et al., 1990) revealed that the first detectable lesionport (Jiang et al., 1998). Thus, although PI 3-kinase acti-
vation is necessary, there is at least one additional path- in insulin action lies in the uptake and storage of glucose
as glycogen in muscle. Although it is likely that theseway involved.
The PI 3-kinase-independent pathway might involve observations were reflective of decreased glucose up-
take in insulin-resistant subjects, glycogen storage isthe tyrosine phosphorylation of the Cbl protooncogene
(Ribon and Saltiel, 1997). This phosphorylation requires typically diminished in patients with Type 2 diabetes,
and may represent a critical event in the pathophysiol-the presence of the adaptor protein CAP, which associ-
ates with a proline-rich domain in Cbl through its car- ogy of the disease. Insulin modulates glycogen accumu-
lation through a coordinated increase in glucose trans-boxy-terminal SH3 domain (Figure 2). CAP expression
correlates well with insulin responsiveness; it is ex- port and glycogen synthesis (Figure 3). The hormone
activates glycogen synthase by promoting its dephos-pressed in insulin-sensitive tissues, markedly induced
during adipocyte differentiation, and is transcriptionally phorylation, via the inhibition of kinases such as PKA
or GSK3 (Cross et al., 1995), and activation of proteinregulated by the thiazolidinedione family of insulin-sen-
sitizing PPARg agonists (Ribon et al., 1998) (see below). phosphatase 1 (PP1) (Brady et al., 1997). Upon its activa-
tion downstream of PI 3-kinase, Akt phosphorylates andUpon phosphorylation, the cbl/CAP complex translo-
cates to a lipid raft domain of the plasma membrane inactivates GSK-3, decreasing the rate of phosphoryla-
tion of glycogen synthase. However, inhibition of GSK-3(Mastick and Saltiel, 1997). Expression of a dominant-
interfering CAP mutant completely inhibited cbl translo- is not sufficient for glycogen synthase activation, since
the kinase does not phosphorylate several residues ofcation and insulin-stimulated glucose uptake (Baumann
et al., 2000). The translocation of phosphorylated cbl the synthase that are dephosphorylated by insulin sig-
naling (Lawrence and Roach, 1997). Moreover, in certainrecruits additional signaling proteins to the lipid raft,
resulting in the activation of the G protein TC10. This model systems, GSK-3 inhibition can be dissociated
from synthase activation, whereas activation of PP1 cor-molecular switch appears to provide a second signal
to the Glut4 protein that functions in parallel with the relates well with changes in glycogen synthase activity
(Brady et al., 1998).activation of the PI 3-kinase-dependent signaling path-
way (Chiang et al., 2001). However, there is no data yet Insulin does not globally activate PP1, but rather spe-
cifically targets discrete pools of the phosphatase, pri-available as to whether this pathway is attenuated in
states of insulin resistance. marily increasing PP1 activity localized at the glycogen
particle. The compartmentalized activation of PP1 byGlut4 and Glucose Transport
Insulin increases glucose transport in fat and muscle insulin is due to glycogen-targeting subunits which
serve as “molecular scaffolds.” bringing together thecells by stimulating the translocation of the transporter
Glut4 from intracellular sites to the plasma membrane. enzyme directly with its substrates glycogen synthase
and glycogen phosphorylase in a macromolecular com-While it is known that insulin-stimulated glucose trans-
port is attenuated in insulin resistance (Shulman, 2000), plex, and in the process exerting profound effects on
PP1 activity in a substrate-specific manner (Newgard etour understanding of the precise mechanisms by which
insulin directs the translocation of Glut4-containing vesi- al., 2000). Four different proteins with some overlap in
tissue distribution, GM, GL, PTG, and R6, have been re-cles to the cell surface remains incomplete. In the basal
state, Glut4 continuously recycles between the cell sur- ported to target PP1 to the glycogen particle. Despite
a proposed common function, no two targeting subunitsface and various intracellular compartments. Insulin
markedly increases the rate of Glut4 vesicle exocytosis, share more than 50% sequence homology, which is
largely confined to the PP1- and putative glycogen bind-and slightly decreases the rate of internalization. Al-
though the mechanisms are unknown, it is likely that ing regions. Overexpression of these scaffolding pro-
teins in cells or in vivo by adenoviral-mediated genethe Glut4-containing vesicle is tethered to intracellular
sites, perhaps defined by a microtubule network (Guil- transfer resulted in a dramatic increase in basal cellular
glycogen levels, even when the extracellular media washerme et al., 2000). Phosphorylation events such as those
catalyzed by PIP3-dependent kinases might release the supplemented with only amino acids in the absence of
glucose (Berman et al., 1998). Furthermore, glycogenvesicle from these sites, allowing for trafficking of Glut4
to the cell surface. stores in the cells infected with PTG were refractory
to breakdown by agents that raise intracellular cAMPThe v-SNARE protein VAMP2 on Glut4-containing
vesicles physically interacts with its t-SNARE counter- levels. These results suggested that PTG overexpres-
sion locks the cell into a glycogenic mode (Newgardpart syntaxin 4 during Glut4 vesicle docking and fusion
with the plasma membrane (Pessin et al., 1999). One et al., 2000). Thus, although glucose transport is rate-
limiting for glycogen synthesis, manipulation of proteinsinteresting possibility is that the PI 3-kinase-indepen-
dent arm of insulin action may be directed at the docking involved in the regulation of synthase and its regulators
can have profound effects on glucose metabolism.and fusion step of Glut4 regulation. Although these
Review
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Figure 3. The Coordinated Regulation of Glu-
cose Uptake and Glycogen Synthesis by In-
sulin
Insulin stimulates the uptake and storage of
glucose in fat and muscle cells. The hor-
mone stimulates transport of glucose, which is
then phosphorylated by hexokinase, and con-
verted into a substrate for glycogen synthase.
This enzyme is regulated by insulin through
allosteric and covalent modifications. Insulin
produces a net reduction in the phosphoryla-
tion state of the enzyme, via inhibition of ki-
nases such as PKA and GSK3, and activation
of the phosphatase PP1. Glucose 6-phos-
phate and UDP-Glucose also allosterically
activate the enzyme, and make it a better
substrate for dephosphorylation. Glycogen
phosphorylase is activated by the calcium-
dependent phosphorylase kinase, and inacti-
vated by dephosphorylation via PP1. These
dephosphorylation events are coordinated by
targeting proteins such as PTG, which as-
sembles these proteins at the glycogen pellet
into a signal reception module for regulation by insulin. IR, insulin receptor; PP1, protein phosphatase 1; PKA, protein kinase A; GSK3, glycogen
synthase kinase 3; GS, glycogen synthase; GP, glycogen phosphorylase; PK, phosphorylase kinase; PTG protein targeting to glycogen; G6P,
glucose 6-phosphate; G1P, glucose 1-phosphate; UDPG, UDP-glucose.
In addition to a primary defect in glucose transport, tance of type 2 diabetes were performed with mono-
genic models of obesity, especially the ob/ob and db/dbevidence exists for reduced glycogen synthase activity
in certain populations (Shulman et al., 1990). A point mice. Investigations by Friedman and others (Friedman,
2000) uncovered the genetic pathways responsible formutation in GM has been associated with altered rates
of glucose metabolism in Danish subjects in vivo (Han- obesity in these strains, defects in the adipocyte-derived
hormone leptin (ob/ob) or its receptor (db/db). In addi-sen et al., 1995) and increased sensitivity to glycogeno-
lytic agents in vitro, although a linkage was not found tion to studies on the regulation of food intake and en-
ergy expenditure by this hormone, investigators havein Japanese patients (Shen et al., 1998). Another muta-
tion in the 39 noncoding region of this gene may cause focused on the mechanism by which this system might
impact on insulin sensitivity. Leptin acts primarily in themRNA instability in Native American populations (Xia et
al., 1998). While it is tempting to speculate about lesions ventromedial hypothalamus, and lesions in this region
of the brain are known to produce hyperinsulinemia andin PP1 or synthase targeting in diabetes, there have
been no reports of widespread changes in any of these insulin resistance, implicating leptin or other centrally
acting peptides in the control of insulin sensitivity. More-genes that might explain reductions in nonoxidative glu-
cose disposal in insulin resistance. over, leptin improves insulin sensitivity in normal rodents
independent of effects on food intake and profoundly
impacts different neuroendocrine pathways that modu-Obesity and Insulin Resistance
As described in an accompanying article (Spiegelman late insulin action (Halaas et al., 1995; Shimomura et
al., 1999b). However, leptin receptors are also found inand Flier, 2001 [this issue of Cell]), a majority of individu-
als suffering from type 2 diabetes are obese, with central many insulin target tissues, and the hormone has been
reported to increase fatty acid oxidation, suggestingvisceral adiposity, and an imbalance in energy intake
and expenditure that leads to numerous metabolic ab- the possibility of a direct effect on the periphery (see
accompanying article by Spiegelman and Flier, 2001,normalities. Insulin resistance might be the result of obe-
sity, but might also contribute to its development. Re- for more discussion).
The Randle Hypothesis Revisitedcent insights into the biology of the adipocyte as an
endocrine organ have supported this latter idea. It is Evidence now suggests that visceral adipocytes may be
relatively resistant to the antilipolytic actions of insulinnow known that this cell type is more than a storage
site for lipids; it also secretes a number of important (Kissebah and Krakower, 1994), and thus might prefer-
entially release NEFAs into the circulation. Indeed, pa-circulating factors, including leptin, TNFa, angiotensin,
and PAI-1, and is the major source for endogenous pro- tients with uncontrolled diabetes typically have abnor-
mally high levels of circulating lipids, especially NEFAs.duction of nonesterified fatty acids (NEFA) via lipolysis
(Kahn and Flier, 2000). Indeed, the dynamic interactions How elevated NEFAs contribute to the dysregulation of
glucose homeostasis, or directly impair insulin sensitiv-between the adipocyte, certain nuclei of the ventrome-
dial hypothalamus and the organs of insulin synthesis ity or insulin secretion remains uncertain, but evidence
is emerging that muscle, liver, and the b cell might beand action insure the coordinated regulation of insulin
sensitivity, as well as energy intake and expenditure. direct targets.
The idea that NEFAs might interfere with insulin actionThe Central Regulation of Insulin Sensitivity
Prior to the development of transgenic and knockout in muscle or liver was introduced by Randle in the 1960s
(Randle et al., 1963). His group observed that increasedtechnologies, most rodent studies on the insulin resis-
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fatty acid flux would lead to increased acetyl CoA in Bergman and coworkers to propose the “single gateway
hypothesis” in which hormonal regulation of lipolysis inmitochondria, which in turn could reduce pyruvate dehy-
drogenase activity, producing an elevation in citrate the adipocyte indirectly controls hepatic glucose output
(Bergman and Ader, 2000). These investigators cite theconcentration. Citrate allosterically inhibits the activity
of phosphofructokinase, leading to an accumulation of observation that the visceral fat is less sensitive to insu-
lin than subcutaneous fat, such that even after a meal,glucose 6-phosphate which in turn inhibits glucose
phosphorylation by hexokinase, thus reducing glucose there is little suppression of lipolysis by the hormone in
this fat depot. The resulting direct flux of fatty acidsutilization, a common feature of insulin resistance and
diabetes. Later studies in humans confirmed the idea, derived from these fat cells through the portal vein to
the liver can directly stimulate glucose production, thussince lipid infusion significantly lowered glucose utiliza-
tion (Roden et al., 1996). However, Randle might not providing a single signal for insulin action and insulin
resistance to the liver, via a visceral fat axis.have accurately predicted the site at which the effect is
exerted. Petersen et al. (1998) showed that fatty acids While this mechanism might help explain the coordi-
nated regulation of glucose and lipid metabolism, therecould interfere with insulin signaling, resulting in de-
creased muscle glucose transport. This reduction in glu- are also clear direct effects of insulin on hepatic gluco-
neogenic and glycogenic enzymes, both through tran-cose transport produced parallel defects in glycogen
synthesis and glucose oxidation in muscle. Since glyco- scriptional and posttranslational mechanisms (O’Brian
and Granner, 1996). Insulin decreases transcription ofgen synthesis accounts for a much larger percentage
of the flux, it accounts for a larger percentage of the the genes encoding gluconeogenic enzymes such as
PEPCK, fructose 1,6 bisphosphatase, and glucose 6-phos-defect. Additionally, recent studies in both rodents and
humans using infusion of lipid while directly measuring phatase, and increases transcription of those encod-
ing glycolytic enzymes such as glucokinase and pyru-insulin action by hyperinsulinemic clamp have repro-
duced the findings observed in patients with insulin re- vate kinase, and lipogenic enzymes such as fatty acid
synthase and acetyl CoA carboxylase. Recent studiessistance, showing a defect in glucose transport and
glycogen synthesis, rather than a direct attenuation of suggest that many of these changes might be mediated
by an increase in levels of the transcription factorglucose oxidation (Dresner et al., 1999).
How does increased NEFA exposure lead to an inhibi- SREBP1-c, whose mRNA levels are increased by insulin
(Kim et al., 1998; Foretz et al., 1999; Shimomura et al.,tion of insulin action in muscle? The primary site may
lie just downstream from the insulin receptor itself. Ele- 1999a). Dominant-negative forms of SREBP1 can block
expression of these gluconeogenic and lipogenic genesvations in plasma NEFAs inhibited the insulin-dependent
tyrosine phosphorylation of IRS1 and its association (Foretz et al., 1999), while overexpression can increase
their expression (Shimomura et al., 1999a). Interestingly,with PI 3-kinase (Dresner et al., 1999). The diminished
activation of this pathway might result from a direct hepatic SREBP levels are increased in rodent models of
lipodystrophy, along with coordinated increases in fattyinteraction of fatty acids or metabolites with compo-
nents of the phosphorylation pathway. In that regard, acid synthesis and gluconeogenesis, the exact phenotype
observed in genetic models of obesity-induced diabetesrecent data indicate a strong correlation between accu-
mulation of intramuscular lipids and insulin resistance, (Shimomura et al., 2000). These observations led Shimo-
mura et al. (2000) to speculate that increased expressionnot only in diabetics, but across a wide range of glucose
tolerant and intolerant subjects with or without obesity of SREBP-1c might lead to the mixed insulin resistance
observed in liver of diabetic rodents, with increased(Perseghin et al., 1999). Transgenic mice that are devoid
of fat are severely insulin resistant, recapitulating the rates of both gluconeogenesis and lipogenesis. The path-
ways that account for the changes in SREBP1-c expres-phenotype observed in patients with lipodystrophy
(Gavrilova et al., 2000). These mice also have a 2-fold sion in response to insulin or other metabolic changes
are not known, but probably lie downstream of theincrease in intramuscular and intrahepatic triglycerides
(Kim et al., 2000), due to the forced partitioning of lipid IRS/PI 3-kinase pathway.
Cytokines and Insulin Resistanceinto muscle and liver. Earlier studies (Boden et al., 1994)
reported a 3 hr lag in the inhibitory effect of lipid infusion, In addition to generating increases in fatty acids, the
development of obesity may provide other critical sig-suggesting that some metabolism or accumulation of
lipid to threshold levels was required. Although all of nals that contribute to insulin resistance. While the cen-
tral nervous system plays an important role in regulatingthe studies reported thus far are correlative in nature,
one interesting possibility is that fatty acid influx or accu- insulin sensitivity, there is also growing evidence that
adipocyte-derived cytokines, particularly TNFa, mightmulation leads to the activation of a serine kinase which
phosphorylates IRS1, reducing its tyrosine phosphoryla- block insulin action. Some, but not all studies have indi-
cated that TNFa may be elevated in states of obesity,tion by the insulin receptor, as discussed above. Schmitz-
Peiffer et al. (1997) have proposed that specific isoforms perhaps reflecting increased adiposity (Peraldi and
Spiegelman, 1998). The cytokine exerts catabolic effectsof protein kinase C might serve this function, although
there are several other possibilities. on the adipocyte, blocking lipid synthesis and lipopro-
tein lipase expression, while activating lipolysis, and canThe Single Gateway Hypothesis of Hepatic
Metabolic Regulation by Fatty Acids block or reverse differentiation of fibroblastic precursors
into adipocytes (Hotamisligil, 1999). These data suggestMuch attention has also focused on the role of NEFAs
in regulating hepatic glucose metabolism. NEFAs can that TNFa might normally function in a feedback path-
way to limit adipocyte number or lipid storage.stimulate gluconeogenesis in the liver, possibly by in-
creasing expression of subunits of the glucose 6-phos- Hotamisligil (1999) has suggested that excessive
TNFa, perhaps at a local level, might mediate obesity-phatase system (Rebrin et al., 1996). These findings led
Review
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induced insulin resistance, although studies with block- rather in an enhanced rate of apoptosis (Pick et al.,
1998). A similar phenotype has been observed in miceing antibodies or knockout of TNFa or its receptors have
in which IRS2 or the insulin or IGF1 receptors have beennot been consistent (Ofei et al., 1996; Ventre et al., 1997;
deleted in a b cell–specific manner (Withers et al., 1998;Schreyer et al., 1998). In vitro studies revealed that TNFa
Kulkarni et al., 1999), suggesting that the insulin or IGF1can impair insulin signaling (Hotamisgil et al., 1996). Al-
receptors signal in a critical way for b cell function orthough the mechanisms have not been fully elucidated,
survival.TNFa may stimulate the serine phosphorylation of IRS
Lipid Metabolism and b Cell Functionproteins, leading to decreased tyrosine phosphorylation
In vitro and in vivo studies have shown that NEFAs canand PI 3-kinase association. Although the kinases that
acutely enhance insulin secretion and support the glu-catalyze these phosphorylations remain unknown, there
cose response (Stein et al., 1996). Suppression of lipoly-are a number of candidates that are suggested in the
sis with nicotinic acid inhibits insulin secretion, althoughcytokine literature, including the MAP kinases, cera-
the mechanism for this action remains unknown. How-mide-activated kinases, and IKB kinase. Studies using
ever, prolonged exposure to NEFAs appears to reduceinhibitors and dominant-negative forms of these en-
insulin secretion, and prevent b cell compensation inzymes may help to clarify the potential role of this
Zucker rats (Carpentier et al., 1999), although it remainspathway. However, interpretation of these in vitro ap-
unclear whether a similar phenomenon occurs in hu-proaches is difficult, since the cytokine can reverse the
mans. The mechanism of “lipotoxicity” in the b cell re-adipogenic phenotype in cultured cells, thus obscurring
mains uncertain. Unger and colleagues have suggestedthe data.
that accumulation of triglycerides increases nitric oxide,
which causes oxidative damage and apoptosis in theDefective Glucorecognition in the b Cell Is Critical
cells (Shimabukuro et al., 1997; Unger et al., 1999).to the Development of Diabetes
As described above, insulin is released from the b cell
Genetics of Human Type 2 Diabetesas a consequence of glucose metabolism, and the de-
Genetic factors profoundly influence insulin sensitivity.velopment of Type 2 diabetes occurs upon the failure
Insulin resistance occurs commonly in relatives of typeof the b cell to compensate adequately for insulin resis-
2 diabetics, and offspring of two type 2 diabetic parentstance by secreting more insulin. Studies in monogenic
are invariably insulin resistant. In addition, studies inobese rodent models of Type 2 diabetes have shown a
monozygotic twins reveal a high heritability of diabetes,general pattern of expansion of b cell mass to compen-
with a 50%–75% estimate in the heritability of insulinsate for increased insulin demand, followed by de-
resistance. Given that genes influence glucose homeo-creased glucose recognition, islet degeneration, de-
stasis, the major question arises as to whether thesegranulation, and loss of b cells (Cavaghan et al., 2000).
traits are the consequence of one or two “major’ genes,There have been few morphological examinations of
or a large number of “minor” genes, that may be ex-pancreata in patients with Type 2 diabetes, yet it is likely
pressed only under the appropriate environmental in-that a similar sequelae occurs. Although the mecha-
sults. While this issue remains unresolved, a number ofnisms underlying this phenomenon remain unknown,
groups have looked at obvious candidate genes, at-
both genetic and environmental factors are thought to
tempting to associate clear differences in metabolic
be involved.
phenotype with mutations or polymorphisms in known
Failure of b Cell Compensation genes. Genes encoding proteins involved in insulin sig-
In addition to an increase in b cell mass, the compensa- naling, glucose transport, glycogen synthesis, fatty acid
tory increase in insulin secretion during states of insulin uptake and synthesis, and adipocyte differentiation
resistance is the result of elevated expression of certain have all yielded associations with diabetes, but in only
genes encoding proteins of glucose metabolism. Both perhaps 2%–5% of patients, suggesting that such syn-
mechanisms are evident in the Zucker fatty rat, which dromes are relatively rare.
develops insulin resistance and hyperinsulinemia, with- In recent years, most investigators in this area have
out progressing to hyperglycemia (Tokuyama et al., focused on identifying diabetes genes via positional
1995). In this rat, the increase in islet mass seems to cloning methods, looking for linkage between regions
reflect b cell proliferation, perhaps with some changes of chromosomal DNA that are shared in affected family
in matrix proteins surrounding the b cells. Increased members. A number of relatively uncommon monogenic
expression of glucokinase and hexokinase also appears forms of the disease, known as maturity-onset diabetes
to contribute to the hypersecretion of insulin, by increas- of the young (MODY), have been attributed to mutations
ing glucose phosphorylation, making more substrate resulting in b cell dysfunction. These patients usually
available for glycolysis. The signal that produces these present in adolescence to early adulthood, with defec-
changes remains uncertain, but may be glucose itself, tive insulin secretion in response to glucose. Five of
or perhaps even insulin, generating a positive feedback these genes include the glucose metabolizing enzyme
loop. glucokinase, transcription factors HNF1a and b, HNF4a,
Unlike the Zucker fatty rat, the male Zucker diabetic and insulin promoter factor 1 (IPF1) (Hattersley, 1998;
fatty rat progresses to frank diabetes due to failure to Permutt and Hattersley, 2000). These mutations can lead
compensate adequately for insulin resistance, sug- to moderate to significant reductions in insulin secretion,
gesting a modifier gene present in one or the other strain with consequent development of hyperglycemia. While
that directly impacts b cell function. Studies on cell the incidence of these monogenic forms of diabetes is
turnover in these animals suggest that the primary de- not precisely known, it may represent up to 5% of all
patients with Type 2 diabetes.fect lies not in an inability of b cells to proliferate but
Cell
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Table 1. Some Therapeutic Targets in Type 2 Diabetes
Protein Class Target Action Aim
Cell Surface Receptors Insulin receptor Agonist Insulin mimetic
Glucagon receptor Antagonist Lower fasting glucose
b-3 Adrenergic receptor Agonist Increase lipolysis
GLP receptor Agonist Increase insulin secretion
Protein kinases AMP-activated kinase Activator Increase glucose transport
Protein kinase C Inhibitor Block receptor desensitization
MAP kinase Inhibitor Block receptor desensitization
Ceramide activated kinase Inhibitor Block receptor desensitization
IkB kinase Inhibitor Block receptor desensitization
GSK-3 Inhibitor Activate glycogen synthase
Protein phosphatases PTP1b Inhibitor Block receptor dephosphorylation
LAR Inhibitor Block receptor dephosphorylation
PP1 Activator Activate glycogen synthase
Lipid Phosphatases SHIP2 Inhibitor Increase PIP3-stimulated
PTEN glucose transport
Adaptor proteins Synip Inhibitor Increase glucose transport
Transcription factors PPARg Selective modulator Insulin sensitizer
HNF4 Selective modulator Increase insulin secretion
Ion channels Sulfonylurea receptor Inhibit K channel Increase insulin secretion
A number of genomic scans have been carried out to opportunities for therapeutic intervention. Recent ad-
vances in mechanisms of signal transduction, cell differ-define the more common polygenic forms of the disease.
Studies concentrating on several ethnic and racial groups entiation, and membrane trafficking have led to new
approaches (Table 1). A major challenge of these effortshave identified a series of linkages across several re-
gions of the genome. The first of these studies to be will include the need to specifically target molecules
that impact on metabolism, without interfering with orcompleted focused on 170 Mexican-American families
in Starr County, Texas, identifying a linkage on Ch2p37 activating other pathways that might lead to unaccept-
able side effects. Thus, it will be necessary to keep in(Hanis et al., 1996). This locus was shown to require
another locus on Ch15 for its effects. The recently cloned mind tissue distribution, cellular location, isotype selec-
tivity and kinetics when designing or searching for mod-gene encodes for a novel calpain, called calpain10
(CAPN10). A pair of haplotypes was found that were ulators of enzymes, receptors, or macromolecular inter-
actions.defined by a polymorphism in an intron, at a site that may
possibly influence transcription of the CAPN10 gene PPARg Modulators Improve Insulin Sensitivity
The thiazolidinedione (TZD) drugs improve insulin resis-(Horikawa et al., 2000). While the genotype is associated
with increased incidence of insulin resistance in Pima tance in a variety of obese and diabetic animal models
and patients (Saltiel and Olefsky, 1996). These drugsIndians, along with a reduction in CAPN10 mRNA levels
(Baier et al., 2000), it has yet to be proven that a genetic reduce plasma glucose levels and concomitantly lower
hyperinsulinemia by improving the stimulation of glu-variation in CAPN10 can cause diabetes. The function
of the CAPN10 protein remains unclear, as does the cose disposal and the inhibition of hepatic glucose pro-
duction by insulin. It is now clear that the antidiabeticmechanism by which it might impact on glucose metab-
olism. Other isoforms of calpain may be involved in sig- actions of TZDs are due to the activation of the peroxi-
some proliferator activated receptor gamma (PPARg)naling or fat cell differentiation. However, there is as of
yet no evidence that CAPN10 has enzyme activity, and (Lehmann et al., 1995), a member of the nuclear receptor
superfamily of transcription factors (Braissant et al.,its role in metabolism or signal transduction remains
unknown. 1996). While the identities of endogenous ligand(s) for
PPARg remain uncertain, various lipid or prostaglandinThe elucidation of the human genomic sequence is
expected to accelerate the identification of diabetes molecules have been proposed (Forman et al., 1995;
Kliewer et al., 1997). PPARg exists as a heterodimer withgenes. However, finding positional candidates will re-
quire strong evidence of linkage between a chromo- the nuclear receptor RXR. The heterodimer binds to
PPAR response elements (PPREs) in the promoters ofsomal region and a metabolic abnormality that predis-
poses to a clinically relevant phenotype, and then proof target genes and recruits a histone acetylase, activating
transcription (Glass and Rosenfeld, 2000).that the genetic variant causes meaningful changes in
function. A major challenge will entail understanding the PPARg activation by ligands correlates well with the
antidiabetic actions of these agents, suggesting thatgene/environment or gene/gene interactions that are
likely to be required for the development of diabetes. regulated expression of PPAR-responsive genes ac-
counts for the insulin-sensitizing effects. However, it has
been difficult to identify precisely the genes that areNew Molecular Targets for Antidiabetic Therapy
The advances in our understanding of the molecular responsible for the reversal of insulin resistance. Thus
far, most of the genes known to change in response topathways that underlie insulin action and secretion
and intermediary metabolism point to a number of new TZDs encode lipogenic proteins that are associated with
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differentiation of adipocytes; few have been found that and LAR has been reported in insulin-resistant patients
(Drake and Posner, 1998). Overexpression of these en-are regulated in terminally differentiated cells. The dis-
covery that the gene encoding the signaling protein CAP zymes in cultured cells prevents insulin receptor kinase
activation. A PTP1b knockout mouse was more insulin(see above) is upregulated by PPARg in mature fat cells,
both in vitro and in vivo, suggests a mechanism for sensitive than control littermates, although it remains
uncertain whether this resulted from a direct improve-increased insulin-stimulated glucose uptake by PPARg
activators (Ribon et al., 1998). Another potential target ment in insulin signaling in all affected tissues (Elchebly
et al., 1999), or an indirect effect due to changes inis the adipocyte-derived protein resistin, the expression
of which is reduced after PPARg activation (Steppan et energy expenditure. In either case, inhibition of PTP1b
represents an obvious target for drug discovery.al., 2001). Resistin may act as a negative regulator of
insulin action, although more characterization of this Since there is evidence that serine kinases may phos-
phorylate and thus inhibit the tyrosine phosphoryla-interesting protein is needed. Moreover, it is possible
and perhaps likely that the PPARg activators operate tion of IRS1 in a variety of experimental paradigms of
insulin resistance, identification of these kinases andthrough secondary mechanisms, including a decrease
in circulating free fatty acid levels or increased oxidation specific inhibitors represents another rich area for anti-
diabetic therapy. Along the same lines, the products ofof lipids in muscle (Saltiel and Olefsky, 1996).
While the search for new activators of PPARg repre- PI 3-kinase play a critical role in insulin action, and might
be reduced in states of insulin resistance. In this regard,sents an obvious target of antidiabetic drug discovery,
genetic variations and knockouts of the receptor have the pathway could also be negatively regulated by poly-
phosphoinositide phosphatases, such as PTEN or SHIP2.complicated the issue. Although homozygous PPARg
null animals were not viable due to placental lethality, SHIP2 has been implicated in regulating insulin sensitiv-
ity (Wada et al., 1999), and might be an attractive targetheterozygous PPARg1/2 mice surprisingly exhibited nor-
mal glucose tolerance in the face of reduced insulin for inhibition, especially considering its restricted ex-
pression in insulin target tissues.levels, suggesting a state of enhanced insulin sensitivity
(Barak et al., 1999; Miles et al., 2000). This paradoxical Targeting Glucose Utilization
As described above, the earliest detectable lesion infinding was confirmed by studies that revealed a sub-
stantial increase in insulin-stimulated glucose disposal insulin resistance involves the stimulation of nonoxida-
tive glucose metabolism by insulin, including glucose(Miles et al., 2000), and in separate studies that showed
a resistance to high fat diet–induced insulin resistance transport, phosphorylation, and storage as glycogen.
While the mechanics of Glut4 translocation remain(Kubota et al., 1999).
Although it is possible that these results reflect an largely unexplained, there are clues about some thera-
peutic targets, including proteins involved in the regula-indirect modulation of insulin resistance through changes
in the metabolic milieu, they suggest that PPARg activa- tion of Glut4 vesicle docking described above. Another
approach emerges from insights into glucose transporttors might not act purely as agonists for the receptor,
but may also antagonize effects of natural ligands at in exercise. Recent studies suggest that the stimulation
of Glut4 translocation in response to acute exercise orsome sites (Camp et al., 2000). Indeed, some TZDs are
partial agonists of PPARg, and different TZDs induce hypoxia utilizes an insulin-independent pathway, possi-
bly involving activation of AMP-activated kinase (Haya-an overlapping but distinct set of genes, suggesting
that the conformation and activity of the TZD/PPARg shi et al., 1998). Although the protein substrates of this
kinase are unknown at present, this enzyme may repre-complex might depend upon ligand structure or pro-
moter context (Camp et al., 2000). These data have led sent an attractive target for development of activators,
which might also produce beneficial effects on lipidsto the concept of the selective PPAR modulator (Olefsky
and Saltiel, 2000). This model expands the signaling (Kemp et al., 1999).
Although untested, it is also possible that direct stimu-repertoire of a specific nuclear receptor, since it would
allow a response to a given endogenous ligand in a lation of glycogen synthesis might mimic or enhance
insulin action. As described above, the phosphorylationway that is gene context specific. Moreover, different
endogenous ligands, working through the same nuclear state of glycogen synthase and phosphorylase are con-
trolled by the kinases GSK3 and PKA, and the phospha-receptor, could hypothetically lead to different re-
sponses in different tissues. Thus, identification of the tase PP1, all of which are potential therapeutic targets.
Although glucose transport is clearly the rate-limitingappropriate “molecular signature” for a ligand, based
on binding properties, molecular structure, cataloged step in glucose utilization, it is possible that the stimula-
tion of glycogen synthesis might sensitize cells to insu-changes in gene expression in target tissues, coactiva-
tor and corepressor binding patterns, and in vivo pheno- lin, via a “pull” mechanism. Appropriate targeting of
molecules that modulate the activities of these enzymestype regarding efficacy and side effect profile, might
lead to the development of rationally designed antidia- is critical, since they are involved in a number of other
processes that critically control cell growth and apopto-betic drugs that are greatly improved over the TZDs.
Targeting Insulin Signaling sis. In this regard, it will be important to take into consid-
eration the scaffolding roles played by the glycogen-The insulin receptor and its signaling pathways are also
a fertile area for drug development. Efforts are underway targeting subunits.
b Cell Targetsto identify small molecule mimics of the receptor (Zhang
et al., 1999), although whether these will lead to effective The most widely used antidiabetic drugs stimulate insu-
lin secretion and are typified by the sulfonylurea class,treatments of insulin resistance remains uncertain. The
receptor might also be negatively regulated by protein which directly inhibit the b cell isoform of a specific K
channel. However, while these drugs are effective intyrosine phosphatases. Elevated expression of PTP1b
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in mice with targeted disruption of the IRS-1 gene. Nature 372,patients with Type 2 diabetes, they have significant side
186–190.effects, and might accelerate the progression of the
Baier, L.J., Permana, P.A., Yang, X., Pratley, R.E., Hanson, R.L.,disease, as well as some of the cardiovascular liabilities
Shen, G.Q., Mott, D., Knowler, W.C., Cox, N.J., Horikawa, Y., et al.associated with hyperinsulinemia. On the other hand,
(2000). A calpain 10 gene polymorphism is associated with reducedrestoration of normal glucose responsiveness of the b
muscle mRNA levels and insulin resistance. J. Clin. Invest. 106,
cell, or prevention of the events leading to decompensa- R69–73.
tion is an important goal of antidiabetic therapy. While
Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P.,
breakthrough therapies will require more insight into the Chien, K.R., Koder, A., and Evans, R.M. (1999). PPARg is required
molecular basis of b cell dysfunction and apoptosis, for placental, cardiac and adipose tissue development. Mol. Cell 4,
585–595.there are a number of candidate targets known from
studies on apoptosis in other systems and glycolytic Baumann, C.A., Ribon, V., Bickel, P.E., Thurmond, D.C., Kanzaki,
M., Pessin, J.E., and Saltiel, A.R. (2000). CAP defines a secondstimulus secretion coupling in the b cell.
signaling pathway required for insulin-stimulated glucose transport.
Nature 407, 202–207.Summary and Future Directions
Bergman, R.N., and Ader, M. (2000). Free fatty acids and the patho-It is clear that research into diabetes and its related
genesis of type 2 diabetes mellitus. Trends Endocrinol. Metab. 9,syndromes is a complex topic. While I have attempted
351–356.to highlight some of the important areas, there are other
Berman, H.K., O’Doherty, R.M., Anderson, P., and Newgard, C.B.subjects that also deserve mention. Some of these in-
(1998). Overexpression of protein targeting to glycogen (PTG) include the important role of endothelial function and nitric
rat hepatocytes causes profound activation of glycogen synthesis
oxide synthase in insulin action (Shankar et al., 2000), independent of normal hormone- and substrate-mediated regula-
counterregulatory hormones such as glucagon and tory mechanisms. J. Biol. Chem. 273, 26421–26425.
amylin (Shah et al., 2000), steroid-induced diabetes Boden, G., Chen, X., Ruiz, J., White, J.V., and Rosetti, L. (1994).
(Strack et al., 1995), gestational diabetes (Kjos and Bu- Mechanism of fatty acid induced inhibition of glucose uptake. J.
Clin. Invest. 93, 2438–2446.chanan, 1999), transcription of the insulin gene (Ohneda
et al., 2000), developmental biology of b cells (Schuldiner Brady, M.J., Nairn, A., and Saltiel, A.R. (1997). The regulation of
glycogen synthase by protein phosphatase 1 in 3T3–L1 adipocytes.et al., 2000), degradation of insulin (Duckworth et al.,
Evidence for a potential role for DARPP-32 in insulin action. J. Biol.1998), peptides that control insulin secretion (Drucker,
Chem. 272, 29698–29703.1999), other central regulators besides leptin (Friedman,
Brady, M.J., Bourbonais, F.J., and Saltiel, A.R. (1998). The activation2000), and the major influence of diabetes on lipoprotein
of glycogen synthase by insulin switches from kinase inhibition toand lipid metabolism (Ginsberg, 2000), to name a few.
phosphatase activation during adipogenesis in 3T3–L1 cells. J. Biol.I have also not discussed advances in gene therapy or
Chem. 273, 14063–14066.
additional therapeutic targets that are under investiga-
Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W.tion, nor have I touched upon many of the animal models
(1996). Differential expression of peroxisome proliferator-activated
that have taught valuable lessons about genetics, me- receptors (PPARs): tissue distribution of PPAR-alpha, -beta and
tabolism, and the complex interactions between tissues -gamma in the adult rat. Endocrinology 137, 354–366.
(Leiter et al., 1998). Bruning, J.C., Michael, M.D., Winnay, J.N., Hayashi, T., Horsch, D.,
The progress in understanding the metabolic staging Accili, D., Goodyear, L.J., and Kahn, C.R. (1998). A muscle-specific
insulin receptor knockout exhibits features of the metabolic syn-of diabetes over the past few years has led to significant
drome of NIDDM without altering glucose tolerance. Mol. Cell 2,advances in the regimen of treatment of this devastating
559–569.disease. Indeed, there are now tools in the therapeutic
Bruning, L., Gautam, D., Burks, D.J., Gillette, J., Schubert, M., Orban,armamentarium that allow for the targeting of both insu-
P.C., Klein, R., Krone, W., Muller-Wieland, D., and Kahn, C.R. (2000).lin resistance and secretion. However, it remains unclear
Role of brain insulin receptor in control of body weight and reproduc-whether current therapeutic approaches truly tackle
tion. Science 289, 2122–2125.
the underlying metabolic defects. Improvements in the
Camp, H.S., Li, O., Wise, S.C., Hong, Y.H., Frankowski, C.L., Shen,treatment or prevention of the disease will depend on
X.-Q., Vanbogelen, R., and Leff, T. (2000). Differential activation of
understanding the underlying molecular pathophysiol- peroxisome proliferator-activated receptor-gamma by Troglitazone
ogy in more detail. Indeed, advances in genetics, signal and Rosiglitazone. Diabetes 49, 539–547.
transduction, and the neurobiology of energy intake and Carpentier, A., Mittelman, S.D., Lamarche, B., Bergman, R.N., Gi-
metabolism should permit a more precise and perhaps acca, A., and Lewis, G.F. (1999). Acute enhancement of insulin secre-
tion by FFA in humans is lost with prolonged FFA elevation. Am J.individualized approach to therapy, allowing us to focus
Physiol. 276, E1055–E1066.the attack where the problem lies. This alone is reason
for optimism. Cavaghan, M.K., Ehrmann, D.A., and Polonsky, K.S. (2000). Interac-
tions between insulin resistance and insulin secretion in the develop-
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